Salarius Pharmaceuticals, Inc.
SLRX
$0.698
-$0.0348-4.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -50.59% | 31.75% | 16.96% | -94.52% | 63.90% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | -80.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -15.00% | -29.58% | 9.94% | -9.25% | -64.81% |
| Change in Net Operating Assets | 250.17% | -267.56% | -5.91% | 139.49% | 53.95% |
| Cash from Operations | 45.27% | -26.53% | 20.81% | 10.40% | 59.69% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -53.08% | 40.21% | 32.35% | -2.01% | -51.93% |
| Issuance of Common Stock | -100.00% | 1,520.97% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -107.82% | 4,950.71% | 83.68% | -2.01% | 20.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7,684.82% | 101.02% | 27.92% | 9.16% | 57.57% |